ArticleACS omega2026
Multimerization and Conjugation to Antiviral and Cytotoxic Payloads Enhance the Activity of Virus-Neutralizing Nanobodies In Vitro.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence and rapid evolution of novel viral pathogens have challenged conventional antibody-based therapeutics, driving the need for versatile strategies with robust and broadly neutralizing antiviral potential. Nanobodies, compact antibody fragments derived from camelid heavy-chain-only antibodies, represent a promising platform for engineering therapeutics with enhanced antiviral capabilities. We explored targeted modifications of three high-affinity SARS-CoV-2 spike-binding nanobodies raised against the Wuhan variant (1H3, 2F8, and 1D10) through oligomerization and conjugation with cytotoxic and antiviral payloads. We evaluated the impact of these modifications on neutralizing or antiviral activities against the Omicron variant (B.1.1.529 BA.1). In addition to increasing molecular weight, which could extend the serum half-life, PEG-mediated tetramerization of the nanobodies enhanced their affinity, and Fc fusion increased neutralizing potency. Importantly, Sortase A-mediated conjugation of nanobodies with ARVI11, a 1,3-diaza-2-oxophenoxazine derivative exhibiting both anti-SARS-CoV-2 activity and cytotoxicity toward infected host cells, significantly enhanced antiviral efficacy, with the effect being dependent on the type of linker used.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.